{"product_id":"alkermes-balanced-scorecard","title":"Alkermes Balanced Scorecard","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Balanced Scorecard for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Alkermes Balanced Scorecard Analysis gives you a structured view of the company’s financial, customer, internal process, and learning and growth priorities. This page already shows a real preview of the actual report content, so you can review the style and substance before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eB\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eenefits\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA Balanced Scorecard helps Alkermes tie its 2 marketed drugs, VIVITROL and ARISTADA, to its CNS pipeline, so leaders can track how Phase 2 and Phase 3 data turn into revenue. In fiscal 2025, Alkermes reported about $1.6 billion in revenue, showing why launch readiness and reimbursement matter as much as science. That one view makes pipeline risk, approval timing, and revenue conversion easier to manage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdherence Metrics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor Alkermes, adherence metrics like persistence, refill rate, and discontinuation are more useful than sales alone because Aristada offers 1-, 2-, 3-, and 6-month dosing, so missed refills are easy to spot. In schizophrenia, nonadherence is linked to higher relapse and hospitalization risk, so these metrics act as real-world benefit proxies. They also show whether the customer keeps therapy on board, not just starts it.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlkermes should track access as closely as clinical data: in FY2025, the company’s revenue was about $1.4 billion, so payer reach still drives real value. A balanced scorecard should flag formulary wins, prior-authorization delay, and net price realization, because a drug with strong efficacy still fails if patients cannot start it. The team’s job is simple: turn approval into filled prescriptions, fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor Alkermes, quality control is a scorecard driver because injectable and formulation-heavy CNS products depend on batch release success, low deviation rates, and tight yield control. Process reliability protects supply continuity, which supports revenue stability and keeps prescriber confidence high. In 2025, that matters even more in a portfolio where one failed lot can disrupt patient access and margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio Balance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePortfolio balance shows whether Alkermes can offset its revenue concentration with breadth across schizophrenia, bipolar I disorder, and multiple sclerosis. In 2025, that matters because the Company depends on a small set of marketed medicines, so even one weaker product can move results fast. It also pushes capital toward programs that can replace or extend value, instead of spreading spend too thin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTracks mix risk across core franchises\u003c\/li\u003e\n\u003cli\u003eImproves capital discipline by program\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Benefits-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlkermes scorecard: turning clinical wins into revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBenefits in Alkermes balanced scorecard center on turning clinical proof into paid use: in FY2025, about $1.4 billion in revenue shows why access, adherence, and refill rates matter. With VIVITROL and ARISTADA, the scorecard helps spot where patients stay on therapy and where payers slow starts. It also links launch wins to cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003cth\u003eBenefit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e$1.4B revenue\u003c\/td\u003e\n\u003ctd\u003eShows conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRefill\/persistence\u003c\/td\u003e\n\u003ctd\u003eShows patient stay\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nAnalyzes Alkermes’s strategic performance across financial, customer, internal process, and learning and growth dimensions\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a quick, structured Balanced Scorecard view of Alkermes to simplify performance tracking and strategic decision-making.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erawbacks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBinary Regulatory Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBinary regulatory risk makes the balanced scorecard look safer than it is for Alkermes plc, because one FDA or EMA decision can outweigh months of KPI gains. A single Phase 3 miss or label restriction can hit the whole pipeline at once, so the scorecard can overstate control in a business where approval odds, not just execution, drive value. For a company with only a small set of marketed assets, one adverse readout can shift revenue, launch timing, and sentiment far more than a strong quarter can fix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNoisy CNS Outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNoisy CNS outcomes make Alkermes harder to compare across schizophrenia and bipolar studies because key tools differ: PANSS has 30 items, while MADRS has 10, and both rely on site scoring and patient reporting. Relapse timing and functional endpoints also vary by protocol, so a win in one trial can look weaker in another. That noise can blur the read-through on LYBALVI and other CNS assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSlow Data Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor Alkermes, slow data cycles can hide a move until the next quarterly report, so a 90-day lag can make revenue, prescription, and trial trends look older than they are. Clinical readouts often come in batches, and by the time a metric shifts, the real trend may already be 2-3 months old. That matters when one late update can move a stock that still has to digest full-year 2025 results. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Setup\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHeavy setup is a real drawback for Alkermes because a useful scorecard needs clean 2025 data across R\u0026amp;D, manufacturing, market access, and sales. That means more reporting work, more system links, and more chances for dashboard noise when figures do not tie out. Alkermes reported $1.53 billion in 2025 revenue, so even small data errors can distort how each function looks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBenchmark Limits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBenchmark limits matter because Alkermes is not a broad, diversified pharma peer. Its mix is narrower, so direct comparisons can distort readouts when rivals have different product portfolios, pipeline stages, and patent-expiry timing. That makes peer scorecards useful for context, but weak as a stand-alone measure of operating strength.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SCORECARD-Content-Drawbacks-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlkermes’ Small 2025 Base Raises Big Trial Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlkermes has a narrow 2025 base, with $1.53 billion revenue, so one FDA or Phase 3 miss can swing the whole Balanced Scorecard more than routine KPI gains can offset.\u003c\/p\u003e\n\u003cp\u003eCNS readouts stay noisy because PANSS has 30 items and MADRS has 10, so site scoring and patient reports can blur trial quality across assets.\u003c\/p\u003e\n\u003cp\u003eThat makes benchmarking weak too, since rivals have broader portfolios and different patent clocks, while 90-day reporting lags can leave 2025 trends stale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDrawback\u003c\/th\u003e\n\u003cth\u003e2025 data point\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration risk\u003c\/td\u003e\n\u003ctd\u003e$1.53 billion revenue\u003c\/td\u003e\n\u003ctd\u003eOne setback can move results fast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial noise\u003c\/td\u003e\n\u003ctd\u003ePANSS 30; MADRS 10\u003c\/td\u003e\n\u003ctd\u003eHarder to compare outcomes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSlow visibility\u003c\/td\u003e\n\u003ctd\u003eAbout 90-day lag\u003c\/td\u003e\n\u003ctd\u003eScorecard can trail reality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAlkermes Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Alkermes Balanced Scorecard analysis document you’ll receive upon purchase—no surprises, just a professional, ready-to-use report. The preview below is taken directly from the full document, so what you see is exactly what you get. Once purchased, you’ll unlock the complete Balanced Scorecard analysis in full detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53670922453334,"sku":"alkermes-balanced-scorecard","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/alkermes-balanced-scorecard.webp?v=1778874884","url":"https:\/\/balancedscorecardexamples.com\/products\/alkermes-balanced-scorecard","provider":"Balanced Scorecard","version":"1.0","type":"link"}